Journal of Clinical Oncology, Vol 15, 1923-1931, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Prognostic importance of thymidylate synthase expression in early breast cancer

BC Pestalozzi, HF Peterson, RD Gelber, A Goldhirsch, BA Gusterson, H Trihia, J Lindtner, H Cortes-Funes, E Simmoncini, MJ Byrne, R Golouh, CM Rudenstam, M Castiglione-Gertsch, CJ Allegra and PG Johnston
National Cancer Institute-Navy Medical Oncology Branch, Division of Clinical Sciences, Bethesda, MD, USA.

PURPOSE: To assess the prognostic importance of thymidylate synthase (TS) expression in breast tumors of patients with early-stage breast cancer, and to determine whether the benefit of chemotherapy (CT) is associated with TS expression. PATIENTS AND METHODS: The level of TS expression was evaluated in 210 node-negative and 278 node-positive patients enrolled onto Trial V of the International Breast Cancer Study Group ([IBCSG] formerly the Ludwig Breast Cancer Study Group) with a median follow-up time of 8.5 years. TS expression was assessed using the immunohistochemical method with the monoclonal antibody TS 106 on paraffin-embedded tissue specimens. RESULTS: High TS expression was associated with a significantly worse prognosis in node-positive but not in node-negative breast cancer patients. Twenty-seven percent of node-positive patients with high TS expression were disease-free at 10 years, compared with 44% of node-positive patients with low TS expression (P = .03). Forty-one percent of patients with node-positive high-TS-expressing tumors were alive after 10 years, compared with 49% of those with low TS expression (P = .06). The association between TS and disease-free survival (DFS) and overall survival (OS) was independent of other prognostic factors such as tumor size, tumor grade, nodal status, vessel invasion, estrogen receptor (ER)/ progestin receptor (PR) status, c-erb B-2, or Ki-67 expression. In node-positive patients, six cycles of standard adjuvant cyclophosphamide, methotrexate, and fluorouracil ([5-FU] CMF) CT improved DFS and OS compared with one cycle of perioperative CMF therapy. The magnitude of this benefit was greatest in patients whose tumors had high TS expression (P < .01 for DFS; P < .01 for OS). Node-negative patients demonstrated no difference in outcome to CT based on TS expression; however, the power to detect differences was limited by the small number of events in this group. CONCLUSION: In early-stage breast cancer, high TS expression is associated with a significantly worse prognosis in node-positive patients. Node-positive patients with high TS levels demonstrate the most significant improvement in DFS and OS when treated with six cycles of conventional adjuvant CMF therapy.

This article has been cited by other articles:

				T. Okabe, I. Okamoto, S. Tsukioka, J. Uchida, T. Iwasa, T. Yoshida, E. Hatashita, Y. Yamada, T. Satoh, K. Tamura, et al. Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase Mol. Cancer Ther., March 1, 2008; 7(3): 599 - 606. [Abstract] [Full Text] [PDF]

				P. Ceppi, M. Volante, A. Ferrero, L. Righi, I. Rapa, R. Rosas, A. Berruti, L. Dogliotti, G. V. Scagliotti, and M. Papotti Thymidylate Synthase Expression in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors Clin. Cancer Res., February 15, 2008; 14(4): 1059 - 1064. [Abstract] [Full Text] [PDF]

				J.-H. Lee, J.-H. Park, Y. Jung, J.-H. Kim, H.-S. Jong, T.-Y. Kim, and Y.-J. Bang Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells Mol. Cancer Ther., December 1, 2006; 5(12): 3085 - 3095. [Abstract] [Full Text] [PDF]

				P. Correale, M. T. Del Vecchio, G. Di Genova, G. G. Savellini, M. La Placa, C. Terrosi, M. Vestri, R. Urso, F. Lemonnier, A. Aquino, et al. 5-Fluorouracil-Based Chemotherapy Enhances the Antitumor Activity of a Thymidylate Synthase-Directed Polyepitopic Peptide Vaccine J Natl Cancer Inst, October 5, 2005; 97(19): 1437 - 1445. [Abstract] [Full Text] [PDF]

				E. K. Wei, E. Giovannucci, J. Selhub, C. S. Fuchs, S. E. Hankinson, and J. Ma Plasma Vitamin B6 and the Risk of Colorectal Cancer and Adenoma in Women J Natl Cancer Inst, May 4, 2005; 97(9): 684 - 692. [Abstract] [Full Text] [PDF]

				Y. C. Hu, R. A. Komorowski, S. Graewin, G. Hostetter, O.-P. Kallioniemi, H. A. Pitt, and S. A. Ahrendt Thymidylate Synthase Expression Predicts the Response to 5-Fluorouracil-based Adjuvant Therapy in Pancreatic Cancer Clin. Cancer Res., September 15, 2003; 9(11): 4165 - 4171. [Abstract] [Full Text] [PDF]

				Y. Mizutani, H. Wada, O. Yoshida, M. Fukushima, M. Nonomura, M. Nakao, and T. Miki Significance of Thymidylate Synthase Activity in Renal Cell Carcinoma Clin. Cancer Res., April 1, 2003; 9(4): 1453 - 1460. [Abstract] [Full Text] [PDF]

				D. C. Farrugia, H. E. R. Ford, D. Cunningham, K. D. Danenberg, P. V. Danenberg, J. Brabender, A. D. McVicar, G. W. Aherne, A. Hardcastle, K. McCarthy, et al. Thymidylate Synthase Expression in Advanced Colorectal Cancer Predicts for Response to Raltitrexed Clin. Cancer Res., February 1, 2003; 9(2): 792 - 801. [Abstract] [Full Text] [PDF]

				S.-B. Lin, P. O. P. Ts'o, S.-K. Sun, K.-B. Choo, F.-Y. Yang, Y.-P. Lim, H.-L. Tsai, and L.-C. Au Inhibition of Thymidylate Synthase Activity by Antisense Oligodeoxynucleotide and Possible Role in Thymineless Treatment Mol. Pharmacol., September 1, 2001; 60(3): 474 - 479. [Abstract] [Full Text] [PDF]

				J. A. Foekens, S. Romain, M. P. Look, P.-M. Martin, and J. G. M. Klijn Thymidine Kinase and Thymidylate Synthase in Advanced Breast Cancer: Response to Tamoxifen and Chemotherapy Cancer Res., February 1, 2001; 61(4): 1421 - 1425. [Abstract] [Full Text]

				S. J. Welsh, J. Titley, L. Brunton, M. Valenti, P. Monaghan, A. L. Jackman, and G. W. Aherne Comparison of Thymidylate Synthase (TS) Protein Up-Regulation after Exposure to TS Inhibitors in Normal and Tumor Cell Lines and Tissues Clin. Cancer Res., June 1, 2000; 6(6): 2538 - 2546. [Abstract] [Full Text]

				D. Edler, M. Hallström, P. G. Johnston, I. Magnusson, P. Ragnhammar, and H. Blomgren Thymidylate Synthase Expression: An Independent Prognostic Factor for Local Recurrence, Distant Metastasis, Disease-free and Overall Survival in Rectal Cancer Clin. Cancer Res., April 1, 2000; 6(4): 1378 - 1384. [Abstract] [Full Text]

				A. S. Haqqani, R. T. Cowling, J. A. Maroun, and H. C. Birnboim Characterization of a Polyclonal Antibody to Human Thymidylate Synthase Suitable for the Study of Colorectal Cancer Specimens J. Histochem. Cytochem., December 1, 1999; 47(12): 1563 - 1574. [Abstract] [Full Text]

				M. R. Posner, P. G. Johnston, R. B. Tishler, J. Andersen, M. Fiorentino, P. M. Busse, L. A. Cavacini, A. D. Colevas, J. Clark, and C. M. Norris The Prognostic Value of Thymidylate Synthase and p53 Expression in Patients Treated with Induction Chemotherapy for Squamous Cell Carcinoma of the Head and Neck Oncologist, December 1, 1998; 3(6): 424 - 431. [Abstract] [Full Text]